Reported 18 days ago
Novo Nordisk's stock experienced a decline after the company revealed that additional weight loss from higher doses of its oral weight-loss drug was limited in recent trial findings. This news raises concerns about the drug's effectiveness and impacts investor confidence, leading to a decrease in the stock's value.
Source: YAHOO